Justin Mencel, MBBS, The Royal Marsden NHS Foundation Trust, London, UK, describes where circulating tumor DNA (ctDNA) is heading in the clinical utility of liquid biopsies. This includes using ctDNA to detect minimal residual disease (MRD) to thereby guide adjuvant treatment decisions, in particular in colorectal cancer (CRC), and as a novel diagnostic tool for the detection of cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
